Sitafloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sitafloxacin
Accession Number
DB13261
Type
Small Molecule
Groups
Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
DU-6859A
Categories
UNII
9TD681796G
CAS number
163253-35-8
Weight
Average: 873.68
Monoisotopic: 872.232645
Chemical Formula
C38H42Cl2F4N6O9
InChI Key
MPORYQCGWFQFLA-ONPDANIMSA-N
InChI
InChI=1S/2C19H18ClF2N3O3.3H2O/c2*20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19;;;/h2*3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28);3*1H2/t2*10-,12+,13+;;;/m00.../s1
IUPAC Name
bis(7-[(7S)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) trihydrate
SMILES
O.O.O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O.N[C@@H]1CN(CC11CC1)C1=C(F)C=C2C(=O)C(=CN([C@@H]3C[C@@H]3F)C2=C1Cl)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcarboseSitafloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AlbiglutideSitafloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlogliptinSitafloxacin may increase the hypoglycemic activities of Alogliptin.Approved
BromocriptineSitafloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
CanagliflozinSitafloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
ChlorpropamideSitafloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DapagliflozinSitafloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DelamanidSitafloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DisopyramideSitafloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DulaglutideSitafloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
EmpagliflozinSitafloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
ExenatideSitafloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
GliclazideSitafloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSitafloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSitafloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideSitafloxacin may increase the hypoglycemic activities of Glyburide.Approved
Insulin AspartSitafloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSitafloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSitafloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSitafloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSitafloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSitafloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
LiraglutideSitafloxacin may increase the hypoglycemic activities of Liraglutide.Approved
MecaserminSitafloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MetforminSitafloxacin may increase the hypoglycemic activities of Metformin.Approved
MifepristoneSitafloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolSitafloxacin may increase the hypoglycemic activities of Miglitol.Approved
NateglinideSitafloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
PentamidineSitafloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PioglitazoneSitafloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PramlintideSitafloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
QuinineSitafloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideSitafloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RosiglitazoneSitafloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SaxagliptinSitafloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SitagliptinSitafloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SulfadiazineSitafloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSitafloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleSitafloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibSitafloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TolazamideSitafloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideSitafloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
27471522
Wikipedia
Sitafloxacin
ATC Codes
J01MA21 — Sitafloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentAcute Pyelonephritis / Infection Due to Escherichia Coli1
2, 3Active Not RecruitingTreatmentAnti-Infective Agents, Urinary / Escherichia Coli Infections / Klebsiella Infections / Transplantation, Kidney / Urinary Tract Infections (UTIs)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.055 mg/mLALOGPS
logP0.24ALOGPS
logP-0.17ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)5.7ChemAxon
pKa (Strongest Basic)9.37ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area86.87 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.09 m3·mol-1ChemAxon
Polarizability38.98 Å3ChemAxon
Number of Rings10ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:38 / Updated on June 02, 2018 08:48